Actinium Pharmaceuticals (ATNM) AI Stock Analysis

• Market Cap: $47.42M
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: -100.00%
• EPS Growth: 30.65%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.27
• Shares Outstanding: 31,195,890
• 10 Day Avg. Volume: 424,186
• 30 Day Avg. Volume: 1,135,024
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.68
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -395.36
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 302.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Actinium Pharmaceuticals faces substantial financial challenges due to declining revenues, net losses, and negative cash flows, contributing to a low overall score. The technical analysis suggests a bearish trend, with the stock trading below key moving averages and negative MACD. The valuation is further weakened by a negative P/E ratio and absence of dividends. These factors significantly impact the stock's attractiveness, resulting in a score towards the lower end of the scale.

Positive Factors

Financial Stability

Actinium has a strong balance sheet, with nearly $79M in cash and no debt, providing financial stability.

Strategic Partnerships

Actinium recently entered into a research agreement with Memorial Sloan Kettering Cancer Center to further develop Actimab-A.

Therapeutic Innovation

ATNM-400 demonstrated anti-tumor activity in prostate models, most notably showing superior tumor growth inhibition versus Pluvicto in vivo.

Negative Factors

Financial Performance

Actinium reported a net loss of ($6.7M) for 4Q24 and ($38.2M) for the full year, ending with $72.9M in cash on the balance sheet.

Regulatory Challenges

The high rate of crossover observed in the SIERRA trial confounded survival analyses and is believed to be a main reason the FDA would not approve Iomab-B without an additional trial.

Actinium Pharmaceuticals Business Overview & Revenue Model

Company Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

How the Company Makes Money

Actinium Pharmaceuticals generates revenue through a combination of partnerships, licensing agreements, and potentially, future sales of its developed therapies. The company's revenue model primarily involves collaborations with larger pharmaceutical companies to co-develop and commercialize its proprietary therapies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. Actinium's focus on advancing its pipeline through clinical trials also positions it to earn revenue from the eventual approval and sale of its therapeutic products. Additionally, the company may engage in research and development agreements with academic and research institutions to further its scientific initiatives.

Actinium Pharmaceuticals Financial Statement Overview

Summary

Actinium Pharmaceuticals faces financial challenges typical for biotechnology firms in the R&D phase, with negative margins and cash flows. Stability is maintained through a low debt profile, but profitability remains elusive. The company's financial health depends on successful research outcomes and potential future revenue growth from product commercialization.

Income Statement

Actinium Pharmaceuticals has shown a significant decline in revenue, with a TTM revenue of $81,000 compared to $1,030,000 in 2022, translating to a steep revenue contraction. Gross profit margin is negative due to a larger cost base than revenue, indicating operational challenges. Net profit margins are also negative, reflecting ongoing financial losses common in the biotechnology sector during early development stages.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity is negative, indicating the company is not generating positive returns from its equity. The equity ratio remains stable, reflecting a balanced asset structure with significant equity capital.

Cash Flow

Free cash flow is negative and has deteriorated further in the TTM period, highlighting cash consumption typical for R&D-intensive biotechnology firms. Operating cash flow is also negative, exceeding net income losses, indicating substantial cash burn. The company relies heavily on financing activities to sustain operations.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
81.00K	1.03M	1.14M	0.00	0.00
	Gross Profit
81.00K	331.00K	620.00K	-447.00K	-420.09K
	EBIT
-51.92M	-34.10M	-24.96M	-22.39M	-22.07M
	EBITDA
-51.13M	-33.41M	-24.44M	-21.77M	-21.48M
	Net Income Common Stockholders
-48.82M	-31.93M	-24.58M	-22.04M	-21.73M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
76.68M	108.91M	77.83M	63.56M	9.25M
	Total Assets
81.44M	114.19M	80.39M	66.40M	11.67M
	Total Debt
2.11M	2.58M	310.00K	738.00K	1.43M
	Net Debt
-74.56M	-106.33M	-77.52M	-62.82M	-7.83M
	Total Liabilities
45.07M	47.71M	6.84M	5.08M	6.03M
	Stockholders Equity
36.38M	66.48M	73.55M	61.32M	5.64M
Cash Flow		Free Cash Flow
-47.49M	8.28M	-21.00M	-21.87M	-21.53M
	Operating Cash Flow
-47.34M	8.64M	-20.87M	-21.62M	-21.46M
	Investing Cash Flow
-153.00K	-366.00K	-133.00K	-253.00K	-63.89K
	Financing Cash Flow
14.87M	23.11M	35.22M	76.18M	17.11M

Actinium Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.49
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Positive. The current price of 1.49 is above the 20-day moving average (MA) of 1.30, above the 50-day MA of 1.31, and below the 200-day MA of 1.93, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.96 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATNM.

Actinium Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
PDSB	50 Neutral	$63.55M	―	-166.65%	―	―	25.51%
HYPR	45 Neutral	$56.82M	―	-61.03%	―	16.84%	9.43%
ATNM	41 Neutral	$47.42M	―	-110.63%	―	-100.00%	30.65%
ANEB	35 Underperform	$49.71M	―	-71.49%	―	―	28.92%
ARMP	33 Underperform	$48.68M	―	81.15%	―	14.24%	72.63%
ALGS	30 Underperform	$36.90M	―	-415.84%	―	-74.60%	―

Actinium Pharmaceuticals Corporate Events

Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes

Actinium Pharmaceuticals, Inc. held its 2024 annual stockholder meeting where Sandesh Seth and Jeffrey W. Chell were re-elected as Class II directors to serve until 2027. Additionally, Marcum LLP was ratified as the independent public accountant for the fiscal year 2024. The meeting saw the participation of 19,724,287 shares, with all proposals receiving approval from stockholders.

Actinium Pharmaceuticals Strengthens Board with New Appointment

Actinium Pharmaceuticals has appointed Dr. June Almenoff, a seasoned biopharma executive with over 25 years of experience in drug development and leadership, to its Board of Directors. Dr. Almenoff’s extensive background in translational medicine and business development, including leading successful product approvals, is expected to bolster Actinium’s strategic vision and innovation in targeted radiotherapies. Her expertise will be invaluable as Actinium aims to enhance its position in the radiopharmaceutical sector, focusing on innovative treatments for oncology patients.